|Click to enlarge. Updated 12/29/15|
Both "local" (via the tumor) and "chemical" (via physical chemistry) are critical constructs for this paradigm shift. As such, can the trials in progress and to be started -- Stage III melanoma Phase 3, Stage IV melanoma, cancers of the liver expanded Phase 1-Phase 1b/2 -- establish in a more widespread manner (widespread from the perspective of awareness) this transition, and thus this shift?
* Clinical value proposition:
- Safe and tissue sparing
- Locally and systemically effective
- Multi-indication viability
- Synergistic combinations
- Ease of physician use and supportive of patient compliance
- Easy to use, re-use, ship, store and handle
- Globally affordable
Why I'm Long Provectus Pharmaceuticals, September 24, 2013 (slightly edited below)
PV-10, a novel oncology compound being developed by Provectus Biopharmaceuticals, exemplifies innovation over incrementalism, meaningful over marginal, productized technology over hypothetical, and changing the world over accepting the status quo, with not an insignificant amount of serendipity over contrivance. In sum, these form the quintessential essence of a paradigm shift in the treatment of cancer.